PIKfyve inhibition induces LRRK2 activation through phosphatidylinositol 3-phosphate and CASM
Life Science Alliance · 2027-01 · 10 (1) · e202603939
DOI: 10.26508/lsa.202603939 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, online erschienen am 06.11.2026. Verfasst von Tomoki Kuwahara und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan kuwahara@m.u-tokyo.ac.jp. Hauptthemen laut MEDLINE: Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Phosphatidylinositol Phosphates, Phosphatidylinositol 3-Kinases, Phosphoinositide-3 Kinase Inhibitors. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MEXT | Japan Society for the Promotion of Science, Ono Medical Research Foundation, Takeda Science Foundation.
Abstract (Originalsprache)
LRRK2 is a Parkinson’s disease–associated kinase that phosphorylates Rab GTPases. Hyperactivation of LRRK2, which is thought to cause Parkinson’s disease, occurs on stressed endolysosomal membranes via conjugation of ATG8 to single membranes (CASM) and Rab, whereas the involvement of specific membrane lipids remained unclear. Here, we found that the inhibition of PIKfyve that metabolizes phosphatidylinositol 3-phosphate (PI3P) induces hyperactivation of LRRK2 and that additional inhibition of the class III phosphoinositide 3-kinase that generates PI3P suppressed LRRK2 hyperactivation. Cellular PI3P levels were indeed elevated when LRRK2 was activated. CASM-induced activation of LRRK2, but not CASM itself, was suppressed by phosphoinositide 3-kinase inhibitors, whereas inhibition of CASM or Rab12/Rab29 suppressed LRRK2 activation induced by PIKfyve inhibitors. LRRK2 and phospho-Rab10 were colocalized with PI3P on LAMP1-positive enlarged vacuoles, and LRRK2 directly bound PI3P in vitro via its N-terminal positively charged amino acids. Together, we propose an updated mechanism of LRRK2 hyperactivation that simultaneously requires CASM, Rab, and PI3P-rich membranes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan kuwahara@m.u-tokyo.ac.jp.
- Department of Neuropathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Lipidome Lab Co., Ltd, Akita, Japan.
- Norwich Medical School, University of East Anglia, Norwich, UK.
- Artificial Intelligence Research Center (AIRC), National Institute of Advanced Industrial Science and Technology (AIST), Tokyo, Japan.
- Department of Dementia Inclusion and Therapeutics, The University of Tokyo Hospital, Tokyo, Japan.
ORCID-Profile: Tomoki Kuwahara, Gen Yoshii, Maria Sakurai, Shoichi Suenaga, Thomas Wileman, Kentaro Tomii, Takeshi Iwatsubo
Förderung
- MEXT | Japan Society for the Promotion of Science
- Ono Medical Research Foundation
- Takeda Science Foundation
- Japan Agency for Medical Research and Development
Zitieren
APA
Kuwahara, T., Yoshii, G., Sakurai, M., Suenaga, S., Nakanishi, H., Jefferson, M., Wileman, T., Tomii, K., & Iwatsubo, T. (2027). PIKfyve inhibition induces LRRK2 activation through phosphatidylinositol 3-phosphate and CASM. Life Science Alliance, 10(1), e202603939. https://doi.org/10.26508/lsa.202603939
Vancouver
Kuwahara T, Yoshii G, Sakurai M, Suenaga S, Nakanishi H, Jefferson M, et al. PIKfyve inhibition induces LRRK2 activation through phosphatidylinositol 3-phosphate and CASM. Life Science Alliance. 2027;10(1):e202603939. doi:10.26508/lsa.202603939
BibTeX
@article{Kuwahara2027,
author = {Kuwahara, Tomoki and Yoshii, Gen and Sakurai, Maria and Suenaga, Shoichi and Nakanishi, Hiroki and Jefferson, Matthew and Wileman, Thomas and Tomii, Kentaro and Iwatsubo, Takeshi},
title = {PIKfyve inhibition induces LRRK2 activation through phosphatidylinositol 3-phosphate and CASM},
journal = {Life Science Alliance},
year = {2027},
volume = {10},
number = {1},
pages = {e202603939},
doi = {10.26508/lsa.202603939}
}
EUVIMED